Image-guided evaluation and monitoring of treatment response in patients with dry eye disease

Qazi, Yureeda; Aggarwal, Shruti; Hamrah, Pedram

doi:10.1007/s00417-014-2618-2

Cited by 26 publications

(21 citation statements)

References 214 publications

(191 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has also been used to make qualitative and quantitative assessments of DED progression and severity (Qazi et al. ).…”

Section: Clinical Data Supporting Inflammation In Dedmentioning

confidence: 99%

“…In DED, IVCM is used to observe squamous abnormalities in corneal and conjunctival epithelia, changes in subepithelial corneal nerve plexus, dysfunctional meibomian glands, as well as the presence of inflammatory cell infiltration, goblet cell density and apoptosis, all good indicators of DED inflammation (Villani et al 2013(Villani et al , 2014. It has also been used to make qualitative and quantitative assessments of DED progression and severity (Qazi et al 2014).…”

Section: Imaging Techniquesmentioning

confidence: 99%

See 1 more Smart Citation

Clinical impact of inflammation in dry eye disease: proceedings of the ODISSEY group meeting

Baudouin

İrkeç

Messmer

et al. 2017

Acta Ophthalmologica

112

127

View full text Add to dashboard Cite

Dry eye disease (DED) is a common, multifactorial ocular condition with major impact on vision and quality of life. It is now well recognized that the pathophysiology of chronic DED can include a cycle of inflammation involving both innate and adaptive immune responses. Recently, in vitro/in vivo models have been used to obtain a better understanding of DED‐related inflammatory processes at molecular/cellular levels although they do not truly reproduce the complex and chronic hallmarks of human DED. In clinical DED research, advanced techniques such as impression cytology, conjunctival biopsy, in vivo confocal microscopy and multiplex tear analyses have allowed an improved assessment of inflammation in DED patients. This was supported by the identification of reliable inflammatory markers including matrix metalloproteinase‐9, human leucocyte antigen‐DR or intercellular adhesion molecule‐1 in tears and impression cytology samples. One of the current therapeutic strategies focuses on breaking the inflammatory cycle perpetuating the ocular surface disease, and preclinical/clinical research has led to the development of promising anti‐inflammatory compounds. For instance, cyclosporine, already approved in the United States, has recently been authorized in Europe to treat DED associated with severe keratitis. In addition, other agents such as corticosteroids, doxycycline and essential fatty acids, through their anti‐inflammatory properties, show encouraging results. We now have a clearer understanding of the inflammatory processes involved in DED, and there is hope that the still emerging preclinical/clinical findings will be translated into new and highly effective therapies for patients in the near future.

show abstract

“…It has also been used to make qualitative and quantitative assessments of DED progression and severity (Qazi et al. ).…”

Section: Clinical Data Supporting Inflammation In Dedmentioning

confidence: 99%

Section: Imaging Techniquesmentioning

confidence: 99%

Clinical impact of inflammation in dry eye disease: proceedings of the ODISSEY group meeting

Baudouin

İrkeç

Messmer

et al. 2017

Acta Ophthalmologica

112

127

View full text Add to dashboard Cite

show abstract

“…18–20 From the two corneal confocal microscopes currently in clinical use, the Heidelberg Retinal Tomograph 3 with the Rostock Corneal Module (HRT3/RCM; Heidelberg Engineering GmBH, Heidelberg, Germany) laser IVCM allows for the visualization and differentiation of hyper-reflective dendritiform immune cells (DCs) 21 and improved visualization of subbasal nerves 22 as compared to the Confoscan 4 (NIDEK Co., Ltd., Aichi, Japan) (Fig. 1).…”

Section: Clinical Immuno-imaging With In Vivo Confocal Microscopymentioning

confidence: 99%

“…20 In addition, although the cornea is the most densely innervated tissue of the body, in vivo assessments in patients have remained problematic. However, laser IVCM now facilitates in vivo assessment and quantification of corneal nerves (Fig.…”

Section: Clinical Immuno-imaging With In Vivo Confocal Microscopymentioning

confidence: 99%

Translational Immunoimaging and Neuroimaging Demonstrate Corneal Neuroimmune Crosstalk

Hamrah

Seyed‐Razavi

Yamaguchi

2016

Cornea

Self Cite

View full text Add to dashboard Cite

Corneal immuno- and neuro-imaging approaches facilitate in vivo analyses of the cornea, including high-resolution imaging of corneal immune cells and nerves. This approach facilitates the analyses of underlying immune and nerve alterations not detected by clinical slit-lamp examination alone. In this review, we describe recent work performed in our translational ocular immunology center with a focus on ‘bench-to-bedside’ and ‘bedside-to-bench’ research. The ability to visualize dendritiform immune cells (DCs) in patients with laser in vivo confocal microscopy (IVCM), recently discovered in the central murine cornea, has allowed us to demonstrated their utility as a potential surrogate biomarker for inflammatory ocular surface diseases. This biomarker for inflammation allows the measurement of therapeutic efficacy of anti-inflammatory drugs and its utility as an endpoint in clinical trials with high inter-observer agreement. IVCM image analyses from our studies demonstrated a significant increase in DC density and size in ocular disease, a positive correlation between DC density and clinical signs and symptoms of disease and pro-inflammatory tear cytokines, and a strong negative correlation between DC density and subbasal nerve density. In conjunction with pre-clinical research investigating the inflammatory state in a partial or fully denervated cornea, our results indicated that corneal nerves are directly involved in the regulation of homeostasis and immune privilege in the cornea.

show abstract

“…5 The role of in vivo confocal microscopy in ocular surface analysis of dry eye and glaucomatous patients has been elucidated. 5,[7][8][9][10][11][12][13][14] Topical cyclosporine has been proven to have a beneficial effect in cases of dry eye disease (DED). 15 In a recent study in rabbit eyes beneficial effects of topical cyclosporine has been demonstrated on adverse ocular surface changes produced by long-term antiglaucoma medications.…”

Section: Introductionmentioning

confidence: 99%

Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications

Saini

Dhiman

Dada

et al. 2015

Eye

View full text Add to dashboard Cite

Purpose To evaluate changes in ocular surface and central corneal sub-basal nerve fiber layer (SBNFL) after topical cyclosporin therapy in chronic glaucoma patients on long-term topical antiglaucoma therapy. Methods A prospective comparative study of ocular surface evaluation of chronic glaucoma patients on long-term topical therapy treated concurrently with a topical cyclosporine 0.05% twice daily for 6 months and controls was done. The study parameters evaluated at recruitment and at the 6-month follow-up included details of topical antiglaucoma medications, visual acuity, intraocular pressure, ocular surface evaluation parameters (TBUT, Schirmers I, ocular surface staining scores and ocular surface disease (OSD) index score (OSDI)), central corneal sensation (Cochet Bonnett aesthesiometer), and central confocal microscopy to study the SBNFL density (SBNFLD). Results Thirty-two eyes of 16 patients with chronic glaucoma and 30 eyes of 15 normal subjects as controls were studied. Mean TBUT, pre/post CsA treatment was 8.67 ± 3.01/12.24 ± 1.83 s (P = 0.007). Mean conjunctival/corneal staining scores pre/post CsA treatment were 3.38 ± 1.93/1.50 ± 0.718 (P = 0.00) /5.19 ± 1.82/1.81 ± 0.78 (P = 0.098), respectively. Mean OSDI pre/post CsA treatment scores were 30.63 ± 14.61/14.76 ± 6.06 (P = 0.007). Mean corneal sensations scores pre/post CsA treatment were 4.64 ± 0.46/4.94 ± 0.39 (P = 0.002). Central corneal SBNFLD pre and post CsA treatment was 8811.35 ± 2985.29/10335.13 ± 4092.064 μm/mm 2 (P = 0.0001).Conclusions Schirmer's test, ocular surface staining scores, OSDI, corneal sensations, and corneal SBNFLD showed a statistically significant improvement following a 6-month concurrent topical CsA therapy.

show abstract

Image-guided evaluation and monitoring of treatment response in patients with dry eye disease

Cited by 26 publications

References 214 publications

Clinical impact of inflammation in dry eye disease: proceedings of the ODISSEY group meeting

Clinical impact of inflammation in dry eye disease: proceedings of the ODISSEY group meeting

Translational Immunoimaging and Neuroimaging Demonstrate Corneal Neuroimmune Crosstalk

Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications

Contact Info

Product

Resources

About